STOCKS TELEGRAPH

Tag: Iterum Therapeutics plc

  • Iterum Therapeutics plc (ITRM) stock drops in Pre-Market today : Here’s to know why

    Shares of the Iterum Therapeutics plc (ITRM) stock were dropping in the pre-market trading session today on July 28, 2021, after rising to a good height in the last trade. ITRM stock price saw a decline of 6.88% to drop at $0.69 a share at the time of this writing. The penny stock went high by 17.53% at the previous closing. Let’s try to figure out the reason behind this fall.

    What’s Happening?

    Iterum Therapeutics plc is the clinical-stage biotechnology stock that develops anti-infectives to treat infectious diseases that cause due to multi-drug resistant pathogens.  ITRM stock is falling in pre-market today despite any obvious reason related to it. No specific news or announcement in today’s date is available to justify the bearish sentiment. ITRM stock dropped 68.73% in the last 30 days and in the past 12 months, the penny stock dropped by 32.64%. Let’s take a look at some recent events of the Iterum.

    ITRM stock received Response Letter from FDA:

    Iterum stock received a complete response letter(CRL) from U.S Food and Drug Administration for its new drug application(NDA) oral sulopenem on July 23, 2021. The FDA did not approve the new drug application in its present form. According to CRL, FDA acknowledged the significant statistical data of the overall response rate of the oral sulopenem against ciprofloxacin in the population resistant to ciprofloxacin. However, FDA mentioned in the CRL that this data is not sufficient and demanded additional data for the approval of the drug.

    FDA recommendations to ITRM stock:

    The FDA recommended Iterum stock to conduct at least one more well-controlled and adequate clinical trial by using a different comparator drug. Moreover, the recommendations also included a nonclinical investigation of the NDA in order to determine the optimal dose prescription. However, this recommendation was not connected with approvability of the drug.

    Financial View of ITRM stock:

    According to the first quarter 2021 financial results, Iterum stock suffered a net loss of  $98.9 million as compared to a $16.1 million net loss in the same quarter of the prior year. The penny stock spent $2.5 million and $3.4 million in R&D expenses and general and administrative expenses respectively. At the end of the first quarter, Iterum had $100.5 million in cash, cash equivalents, and short-term investments.

    Wrap Up:

    The penny stock is now red in Wednesday’s pre-market trading session after a strong gain in the last trade. ITRM stock has a market cap of 132.7 million and a 13,786,501 average trading volume.

  • Is This Why The Iterum Therapeutics (ITRM) Stock Fell Pre-Hours Today?

    Iterum Therapeutics plc (ITRM) fell -43.37% to $0.64 at the last check in premarket trading sessions on Monday. To complete the last trading session, ITRM stock declined by -2.59% to $1.13. There was a price range between $1.0761 and $1.17 for Iterum shares. On average, ITRM traded 13.67 million shares daily over the last 100 days, which was above its volume of 12.07 million shares traded on the day.

    Over the last five days, ITRM shares have lost -2.59 percent, while they have lost -43.78% over the last month. Since the ITRM stock is falling in absence of any current news, we can draw our attention to recent developments to gain a better understanding of ITRM.

    Have things been going well at Iterum Therapeutics lately?

    Known for developing differentiated anti-infectives aimed at combating the global challenge of multi-drug resistant pathogens, ITRM stock mission is to significantly improve the health and wellbeing of patients suffering from life-threatening diseases around the globe. ITRM is in Phase 3 clinical development of sulopenem, a drug compound for anti-infective agents that is derived from penems, with an oral and IV formulation. Various gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics have shown potent in vitro activity against sulopenem.

    A letter was recently received by Iterum from the US Food and Drug Administration (“FDA”).

    • As part of its ongoing review of ITRM stock New Drug Application (NDA), the FDA noted deficiencies that prevent the continuation of discussions about labeling and post-marketing requirements while the assessment of the NDA is ongoing.
    • FDA’s notification did not contain any information concerning deficiencies.
    • Additionally, the letter states a decision has not yet been made regarding the information being reviewed.
    • In a letter dated January 21, 2021, the FDA assigned a target date of July 25 for the completion of its review of the NDA under the Prescription Drug User Fee Act (“PDUFA”).
    • ITRMS aims to work with the FDA to understand the specific issues and resolve them quickly.

    How ITRM will be rectifying the deficiencies?

    Despite being disappointed by this news, ITRM stock management remains confident in sulopenem’s ability to help address the growing problem of antibiotic resistance. As a result, ITRM set out to work with the FDA to identify and resolve the issues efficiently to encourage its continued advancement.

    Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. ITRM stock is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. The NDA for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen has been accepted for review by the FDA and a PDUFA goal date of July 25, 2021, has been assigned to it.